TG Therapeutics(US:TGTX) ZACKS·2026-01-14 16:55Core Insights - TG Therapeutics (TGTX) shares increased nearly 7% in after-hours trading after the release of preliminary fourth-quarter and full-year 2025 results that exceeded expectations [1] - The company provided optimistic guidance for 2026, highlighting key anticipated milestones related to Briumvi label expansion studies and other pipeline candidates [1] Financial Performance - TG Therapeutics expects total global revenues of approximately $616 million for full-year 2025, surpassing the previous guidance of $600 million and the Zacks Consensus Estimate of $604 million [3] - Briumvi U.S. net product revenues are projected to be around $182 million for the fourth quarter of 2025 [3] - For full-year 2025, Briumvi net product sales are expected to be approximately $594 million in the United States, exceeding the November guidance of around $585 million [4] 2026 Outlook & Pipeline Goals - TGTX anticipates 2026 revenues in the range of $875 million to $900 million, including $825 million to $850 million from U.S. Briumvi sales, indicating potential double-digit year-over-year growth compared to expected 2025 figures [7][8] - The company expects operating expenses of around $350 million for the full year 2026 [8] - Key milestones for 2026 include the announcement of pivotal topline data from the ENHANCE study, which aims to consolidate Briumvi infusions, and results from the subcutaneous Briumvi formulation [9][10] - TG Therapeutics is also developing azer-cel, an allogeneic CD19-directed CAR T-cell therapy, with preliminary phase I data expected in the second half of 2026 [11]